Technical Analysis for NVO - Novo Nordisk A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical NVO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Crossed Above 20 DMA | Bullish | -0.95% | |
| Gapped Up | Strength | -0.95% | |
| Up 3 Days in a Row | Strength | -0.95% | |
| Up 4 Days in a Row | Strength | -0.95% | |
| Up 5 Days in a Row | Strength | -0.95% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.14% | |
| Up 3 Days in a Row | Strength | 0.14% | |
| Up 4 Days in a Row | Strength | 0.14% | |
| Oversold Stochastic | Weakness | 0.14% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 2x Volume Pace | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 1% | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| Gap Down Partially Closed | 1 day ago |
Get a Trading Assistant
- Earnings date: ???
Novo Nordisk A/S Description
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Diabetes Pharmaceutical Products Inflammation Endocrine System Insulin Hormones Obesity Biopharmaceuticals Peptide Hormones Growth Hormone Glucagon Like Peptide 1 Pharmaceuticals Segment Anti Diabetic Drugs Diabetes Care Growth Hormone Therapy Haemophilia Hormone Therapy Novo Nordisk Related Delivery Systems
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 107.24 |
| 52 Week Low | 63.22 |
| Average Volume | 1,077,229 |
| 200-Day Moving Average | 79.96 |
| 50-Day Moving Average | 97.37 |
| 20-Day Moving Average | 101.84 |
| 10-Day Moving Average | 100.67 |
| Average True Range | 1.50 |
| ADX | 22.78 |
| +DI | 28.26 |
| -DI | 26.55 |
| Chandelier Exit (Long, 3 ATRs) | 102.74 |
| Chandelier Exit (Short, 3 ATRs) | 103.56 |
| Upper Bollinger Bands | 105.76 |
| Lower Bollinger Band | 97.92 |
| Percent B (%b) | 0.45 |
| BandWidth | 7.69 |
| MACD Line | 0.70 |
| MACD Signal Line | 1.09 |
| MACD Histogram | -0.3879 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 103.44 | ||||
| Resistance 3 (R3) | 103.50 | 102.90 | 103.10 | ||
| Resistance 2 (R2) | 102.90 | 102.38 | 102.86 | 102.99 | |
| Resistance 1 (R1) | 102.15 | 102.06 | 101.85 | 102.09 | 102.87 |
| Pivot Point | 101.55 | 101.55 | 101.40 | 101.51 | 101.55 |
| Support 1 (S1) | 100.80 | 101.03 | 100.50 | 100.73 | 99.95 |
| Support 2 (S2) | 100.20 | 100.71 | 100.16 | 99.83 | |
| Support 3 (S3) | 99.45 | 100.20 | 99.72 | ||
| Support 4 (S4) | 99.38 |
